A Study of the Safety and PK of PCS6422 (Eniluracil) With Capecitabine in Patients With Advanced, Refractory GI Tract Tumors

Advanced Cancer Clinical Trial

Official title:

A Phase 1b Dose-escalation Study of the Safety and Pharmacokinetics of Fixed-dose PCS6422 With Escalating Doses of Capecitabine Administered Orally to Patients With Advanced, Refractory Gastrointestinal Tract Tumors

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04861987
• Other study ID #: PCS6422-GI-01
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: June 18, 2021
• Est. completion date: August 10, 2024

Study information

• Verified date: June 2024
• Source: Processa Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is an open label, multicenter study in patients who have advanced, relapsed refractory GI cancer or are not relapsed/refractory but are intolerant to other therapies who, in the judgment of investigators, are candidates for fluoropyrimidine monotherapy.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 23
• Est. completion date: August 10, 2024
• Est. primary completion date: June 29, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Has advanced, metastatic or unresectable GI tract tumors that are refractory or intolerant to existing available therapies and for whom the investigator recommends fluoropyrimidine monotherapy.

2. Has measurable disease in accordance with Respond Evaluation Criteria in Solid Tumors (RECIST) guidelines (Version 1.1).

3. Is aged =18 years

4. Has not received treatment with intravenous (IV) 5 FU or oral 5 FU analogs in the 4 weeks preceding enrollment

5. Has Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2 at study entry

6. Has adequate bone marrow, liver, and renal function as assessed by the following laboratory requirements conducted within 7 days before starting study treatment:

1. peripheral ANC of =1.5 × 109/L

2. platelet count of =75 × 109/L without growth factor/transfusion

3. hemoglobin =8.5 g/dL without growth factor/transfusion

4. estimated glomerular filtration rate >50 mL/min

5. total bilirubin <2 × upper limit of normal (ULN); <5 × ULN if patient has liver metastases, biliary tract cancer; or =3 × ULN if the patient has Gilbert's disease

6. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) <2.5 × ULN, with liver metastasis <5 × ULN

7. international normalized ratio (INR) <1.5

7. Has a life expectancy of at least 12 weeks

8. Female patients of childbearing potential and male patients with partners capable of reproduction must agree to use an effective contraceptive method from the time of Screening through 60 days after the last dose of capecitabine

9. Females of childbearing potential must have a negative serum ß human chorionic gonadotropin pregnancy test result

10. Willingly provides written, informed consent.

11. Has resolution or stabilization of acute toxicity from prior therapy to Grade <2 - except Grade 2 neuropathy

12. If patient has human immune deficiency virus (HIV) infection, it is controlled with undetectable viral load with antiretroviral treatment.

13. If patient has hepatitis C infection and received antiviral treatment, has a negative viral load at Screening

14. If patient has chronic hepatitis B infection and is receiving antiviral treatment, has a negative viral load at Screening.

15. Is willing and able to comply with all protocol required visits and assessments

Exclusion Criteria:

1. Is unable to take oral medication or malabsorption syndromes potentially interfering with medication absorption (e.g., short bowel syndrome or chronic, partial bowel obstruction)

2. Has history or presence of clinically significant abnormal 12 lead ECG results, in the investigator's opinion

3. Has current brain metastasis

4. Has prolonged QTc (with Fridericia's correction) of >480 msec in men and women performed at Screening

5. Has a history of prolonged QTc interval, ventricular tachycardia/fibrillation or significant ventricular arrhythmia, or Torsades de Pointes, or a history of ventricular ablation for arrhythmia

6. Has congenital long QT syndrome or a family history of long QT syndrome

7. Has other clinically significant cardiac disease including, but not limited to, uncontrolled angina, myocardial ischemia or infarction within 6 months, congestive heart failure >Class II per the New York Heart Association, or history of myocarditis

8. Has an electrolyte disturbance, such as uncorrected hypokalemia/hyperkalemia, hypomagnesemia, or hypocalcemia. Patients can be enrolled following successful correction of an electrolyte disturbance.

9. Is currently using any drugs included in the prohibited medications list in the protocol (including those that can prolong QTc) that cannot be discontinued

10. Has known hypersensitivity to any of the components of study treatments

11. Has other primary cancer requiring treatment within the last 3 years, except for cervical intraepithelial neoplasia, ductal carcinoma in situ, or completely excised squamous or basal cell carcinoma

12. Is a pregnant or lactating female

13. Had major surgery, open biopsy, or significant traumatic injury within 4 weeks prior to the first dose of study treatment

14. Is receiving or has received any investigational treatment within 4 weeks prior to study entry, or participating in another clinical study

15. Has known DPD deficiency

Related Conditions & MeSH terms

• Advanced Cancer
• Refractory Cancer
• Stomach Neoplasms
• Tumor Gastric

Intervention

Drug:
• PCS6422 and capecitabine
PCS6422 is an experimental drug that, when combined with capecitabine, may make the immune response more active against cancer. Capecitabine is a commonly used oral fluoropyrimidine.

Locations

Country	Name	City	State
United States	Processa Clinical Site	Cleveland	Ohio
United States	Processa Clinical Site	Fairfax	Virginia
United States	Processa Clinical Site	New Brunswick	New Jersey
United States	Processa Clinical Site	New York	New York
United States	Processa Clinical Site	Omaha	Nebraska
United States	Processa Clinical Site	Santa Fe	New Mexico

Sponsors (1)

Lead Sponsor	Collaborator
Processa Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with dose limiting toxicities (DLT) and incidence of adverse events as assessed by CTCAE v5.0	Frequency, duration, and severity of DLTs and adverse events (AEs)	~6 months
Primary	Maximum Plasma Concentration (Cmax) of capecitabine	To evaluate the Maximum Plasma Concentration (Cmax) of capecitabine	~14 days
Secondary	QTc effect of PCS6422	To evaluate the effect of PCS6422 on QTc	~6 months
Secondary	Maximum Plasma Concentration (Cmax) of PCS6422	To evaluate the Maximum Plasma Concentration (Cmax) of PCS6422	~14 days
Secondary	Number of participants with Adverse Events of Special Interest (AESI)	Frequency, duration and severity of AESIs	~6 months